Expert Review of Anticancer Therapy

Aims & Scope

Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.

Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines.

All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.

Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.8
2024	2.90

SJR (SCImago Journal Rank)

Year	Value
2024	0.926

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	88

Journal Rank

Year	Value
2024	5473

Journal Citation Indicator

Year	Value
2024	1041

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Current and future therapeutic approaches for osteosarcoma

  Citation: 560

  Authors: Douglas J., David S., Jonathan D., Valerae O., Richard

• The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care

  Citation: 447

  Authors: Emily Z., Jeffrey E.

• HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

  Citation: 379

  Authors: Devika, Sarat

• Overview and recent advances in the treatment of neuroblastoma

  Citation: 334

  Authors: Sarah B., Valeria, Erin, Sibo, Scott, Peter E.

• Chemotherapy resistance in osteosarcoma: current challenges and future directions

  Citation: 303

  Authors: Alexander J, Richard

• Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

  Citation: 287

  Authors: Elizabeth, Susan E

• Nonhistone protein acetylation as cancer therapy targets

  Citation: 257

  Authors: Brahma N, Guanghua, Yi L, Jinping, Sean C, Shi-Wen

• A new understanding in the epidemiology of melanoma

  Citation: 254

  Authors: Esther, Salina M

• Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors

  Citation: 238

  Authors: Cliona, Fahd, Richard, Cody, Robin, Robert W, Erin R, William D, Susan E

• Inflammation in the development of lung cancer: epidemiological evidence

  Citation: 233

  Authors: Eric A

---